Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Palova

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Neoplasma|March 15, 2018
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single centerM Palova, T Szotkowski, A Hlusi, et al.
Clinical Laboratory|October 2, 2018
Thrombin Generation Testing in Patients with MyelofibrosisM Palova, L Slavik, A Hlusi, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 17, 2019
Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and ApixabanL Slavik, J Jacova, D Friedecky, et al.
Leukemia|April 27, 2016
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonistsV De Stefano, M Ruggeri, F Cervantes, et al.
Blood Cancer Journal|November 5, 2016
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patientsV De Stefano, A M Vannucchi, M Ruggeri, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Neoplasma|March 15, 2018
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single centerM Palova, T Szotkowski, A Hlusi, et al.
Clinical Laboratory|October 2, 2018
Thrombin Generation Testing in Patients with MyelofibrosisM Palova, L Slavik, A Hlusi, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 17, 2019
Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and ApixabanL Slavik, J Jacova, D Friedecky, et al.
Leukemia|April 27, 2016
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonistsV De Stefano, M Ruggeri, F Cervantes, et al.
Blood Cancer Journal|November 5, 2016
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patientsV De Stefano, A M Vannucchi, M Ruggeri, et al.
Pageof 1